ABUS vs. IGMS, AVTE, YMAB, APLT, KALV, ALT, VERV, SIGA, ATXS, and CMPS
Should you be buying Arbutus Biopharma stock or one of its competitors? The main competitors of Arbutus Biopharma include IGM Biosciences (IGMS), Aerovate Therapeutics (AVTE), Y-mAbs Therapeutics (YMAB), Applied Therapeutics (APLT), KalVista Pharmaceuticals (KALV), Altimmune (ALT), Verve Therapeutics (VERV), SIGA Technologies (SIGA), Astria Therapeutics (ATXS), and COMPASS Pathways (CMPS). These companies are all part of the "pharmaceutical preparations" industry.
Arbutus Biopharma (NASDAQ:ABUS) and IGM Biosciences (NASDAQ:IGMS) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, analyst recommendations, profitability, dividends, earnings and community ranking.
43.8% of Arbutus Biopharma shares are held by institutional investors. Comparatively, 42.8% of IGM Biosciences shares are held by institutional investors. 4.0% of Arbutus Biopharma shares are held by company insiders. Comparatively, 56.9% of IGM Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Arbutus Biopharma received 362 more outperform votes than IGM Biosciences when rated by MarketBeat users. Likewise, 70.83% of users gave Arbutus Biopharma an outperform vote while only 49.22% of users gave IGM Biosciences an outperform vote.
In the previous week, Arbutus Biopharma had 3 more articles in the media than IGM Biosciences. MarketBeat recorded 6 mentions for Arbutus Biopharma and 3 mentions for IGM Biosciences. IGM Biosciences' average media sentiment score of 0.63 beat Arbutus Biopharma's score of 0.32 indicating that IGM Biosciences is being referred to more favorably in the news media.
Arbutus Biopharma presently has a consensus target price of $4.33, suggesting a potential upside of 45.41%. IGM Biosciences has a consensus target price of $17.89, suggesting a potential upside of 94.02%. Given IGM Biosciences' higher possible upside, analysts plainly believe IGM Biosciences is more favorable than Arbutus Biopharma.
Arbutus Biopharma has a beta of 2.05, meaning that its share price is 105% more volatile than the S&P 500. Comparatively, IGM Biosciences has a beta of 0.27, meaning that its share price is 73% less volatile than the S&P 500.
Arbutus Biopharma has a net margin of -572.81% compared to IGM Biosciences' net margin of -11,255.25%. Arbutus Biopharma's return on equity of -62.68% beat IGM Biosciences' return on equity.
Arbutus Biopharma has higher revenue and earnings than IGM Biosciences. Arbutus Biopharma is trading at a lower price-to-earnings ratio than IGM Biosciences, indicating that it is currently the more affordable of the two stocks.
Summary
Arbutus Biopharma beats IGM Biosciences on 12 of the 18 factors compared between the two stocks.
Get Arbutus Biopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for ABUS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ABUS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Arbutus Biopharma Competitors List
Related Companies and Tools
